Quick Update for Amgen (AMGN) Investors

Shares of Health Care sector company Amgen moved -0.6% today, and are now trading at a price of $271.19. The large-cap stock's daily volume was 813,981 compared to its average volume of 2,490,976. The S&P 500 index returned a 0.0% performance.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company is based in Thousand Oaks and has 25,200 full time employees. Its market capitalization is $145,132,240,896. Amgen currently offers its equity investors a dividend that yields 3.1% per year.

22 analysts are following Amgen and have set target prices ranging from $174.47 to $301.79 per share. On average, they have given the company a rating of buy. At today's prices, AMGN is trading 4.79% away from its average analyst target price of $258.8 per share.

Over the last year, AMGN shares have gone down by -6.0%, which represents a difference of -21.0% when compared to the S&P 500. The stock's 52 week high is $296.67 per share and its 52 week low is $211.71. Although Amgen's average free cash flow over the last 6 years has been $9.3 Billion, they have been decreasing at an average rate of -1.4%. For this reason, investors may continue to shun the stock.

Date Reported Cash Flow from Operations ($ k) Capital expenditures ($ k) Free Cash Flow ($ k) YoY Growth (%)
2023 10,800,000 1,115,000 9,685,000 10.24
2022 9,721,000 936,000 8,785,000 4.82
2021 9,261,000 880,000 8,381,000 -15.25
2020 10,497,000 608,000 9,889,000 15.9
2019 9,150,000 618,000 8,532,000 -19.19
2018 11,296,000 738,000 10,558,000
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.